<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01630187</url>
  </required_header>
  <id_info>
    <org_study_id>CARB-011</org_study_id>
    <nct_id>NCT01630187</nct_id>
  </id_info>
  <brief_title>Comparison of Two Doses of Carbetocin for Prevention of Uterine Atony, During Elective Cesarean Section</brief_title>
  <official_title>Comparison of Two Doses of Carbetocin for Prevention of Uterine Atony During Elective Cesarean Section: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laval University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laval University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effectiveness of two doses of carbetocin (50 mcg
      vs 100 mcg) in preventing uterine atony during elective cesarean section.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Postpartum hemorrhage is a major cause of mortality and morbidity in the world, and it is
      most often caused by uterine atony. To prevent this complication, uterotonic medication is
      used during elective cesarean section.

      Carbetocin, a long-acting synthetic analogue of oxytocin, has been used for this purpose for
      many years. This medication has numerous side effects: hypotension, tachycardia, nausea,
      vomiting, chest pain, etc. Using a smaller dose of carbetocin might lower the incidence of
      these side effects, without compromising prevention of uterine atony in a low-risk group of
      patient.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Utilization of a second uterotonic drug</measure>
    <time_frame>First 48 hours of the postpartum</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of side effects</measure>
    <time_frame>During the fifteen minutes following the administration of carbetocin</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of major complications</measure>
    <time_frame>First 48 hours of the postpartum</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drop in hemoglobin measurement</measure>
    <time_frame>on the second post-partum day</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Uterine Atony</condition>
  <condition>Post-partum Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Carbetocin 100 mcg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Carbetocin 50 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carbetocin</intervention_name>
    <description>Administration of carbetocin 50 mcg , after clamping the umbilical cord</description>
    <arm_group_label>Carbetocin 50 mcg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carbetocin</intervention_name>
    <description>Administration of carbetocin 100 mcg , after clamping the umbilical cord</description>
    <arm_group_label>Carbetocin 100 mcg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥ 18 years old

          -  ≥ 37-week pregnancy

          -  singleton pregnancy

          -  elective cesarean section with a low transverse incision

          -  ASA I or II

        Exclusion Criteria:

          -  Personal history of uterine atony or postpartum hemorrhage

          -  Abnormal placental implantation (known or suspected)

          -  &gt; 3 cesarean sections in the past

          -  Personal history of a classic uterine incision

          -  Estimated fetal weight &gt; 4500g

          -  Hemoglobin &lt; 100 g/L

          -  Regular use of tocolytic drugs

          -  Cesarean section under general anesthesia

          -  Known allergy to carbetocin

          -  Refusal

          -  Inability to obtain informed consent
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julie Bédard</last_name>
    <role>Principal Investigator</role>
    <affiliation>Laval University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Saint-François-d'Assise (CHUQ)</name>
      <address>
        <city>Quebec</city>
        <zip>G1L 3L5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 17, 2012</study_first_submitted>
  <study_first_submitted_qc>June 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2012</study_first_posted>
  <last_update_submitted>May 27, 2013</last_update_submitted>
  <last_update_submitted_qc>May 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 29, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Carbetocin</keyword>
  <keyword>Uterotonic drug</keyword>
  <keyword>elective cesarean section</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Postpartum Hemorrhage</mesh_term>
    <mesh_term>Uterine Inertia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carbetocin</mesh_term>
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

